4-(2,5,8,11-tetraoxatridecan-13-yloxy)aniline | 176657-14-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2,5,8,11-tetraoxatridecan-13-yloxy)aniline
• 英文别名: 4-((2,5,8,11-Tetraoxatridecan-13-yl)oxy)aniline；4-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]aniline
• CAS: 176657-14-0
• 化学式: C₁₅H₂₅NO₅
• 分子量: 299.367
• InChiKey: PLAAYRWHJRTICV-UHFFFAOYSA-N

物化性质

• 沸点：
  425.1±40.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  21
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  72.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  光气 、 4-(2,5,8,11-tetraoxatridecan-13-yloxy)aniline 以 乙酸乙酯 为溶剂， 反应 6.0h， 以75%的产率得到
  参考文献：
  名称：

  Liu, H.; Lee, H. S.; Okamoto, Y., Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 160, p. 331 - 338

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5,8,11-四氧杂十三烷-13-基甲磺酸酯 在 sodium hydroxide 、 sodium hydride 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 生成 4-(2,5,8,11-tetraoxatridecan-13-yloxy)aniline
  参考文献：
  名称：

  Liu, H.; Lee, H. S.; Okamoto, Y., Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 160, p. 331 - 338

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ PROTÉINE TYROSINE KINASE
  申请人：METHYLGENE INC

  公开号：WO2013044361A1

  公开（公告）日：2013-04-04

  The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

  本发明提供了用于治疗对激酶活性抑制敏感的疾病的新化合物和方法，例如对蛋白酪氨酸激酶活性抑制敏感的疾病，例如对生长因子受体蛋白酪氨酸激酶活性抑制敏感的疾病，例如对受体型酪氨酸激酶信号抑制敏感的疾病，或例如对VEGF受体信号抑制敏感的疾病。
• [EN] PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES<br/>[FR] PYRROLOBENZODIAZÉPINES ET CONJUGUÉS CIBLÉS
  申请人：SEATTLE GENETICS INC

  公开号：WO2013055990A1

  公开（公告）日：2013-04-18

  A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of formula wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon doub!e bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is S02M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.

  一种化合物、其药学上可接受的盐或溶剂化物、或其共轭物，所选自以下公式组成的群体：其中：（a）R10为H，而R11为OH、ORA，其中RA为饱和的C1-4烷基；（b）R10和R11在它们所结合的氮和碳原子之间形成一个氮-碳双键；或者（c）R10为H，而R11为S02M，其中z为2或3，M为一价的药学上可接受的阳离子，或者M两者共同为二价的药学上可接受的阳离子。
• HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
  申请人：An Haoyun

  公开号：US20090048271A1

  公开（公告）日：2009-02-19

  Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a heteroaryl five-membered ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

  本发明揭示了具有融合的双环杂芳环系统，其中含有一个杂环五元环的杂环取代的新化合物。这些化合物可以抑制多种类型的癌细胞的生长，因此可用于治疗癌症。这些化合物的疗效是通过一种监测细胞生长/迁移的系统来证明的，该系统显示它们是癌细胞生长和/或迁移的有效抑制剂。此外，本发明的化合物已被证明能够停止体内肿瘤的生长，并减小体内肿瘤的大小。本发明还揭示了包含这些化合物的组合物以及使用这些化合物和组合物治疗癌症的方法。
• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：METHYLGENE INC.

  公开号：US20130096088A1

  公开（公告）日：2013-04-18

  The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

  本发明提供了新的化合物和方法，用于治疗对激酶活性抑制有反应的疾病，例如对蛋白酪氨酸激酶活性抑制有反应的疾病，例如对生长因子受体蛋白酪氨酸激酶活性抑制有反应的疾病，例如对受体型酪氨酸激酶信号抑制有反应的疾病，或例如对VEGF受体信号抑制有反应的疾病。
• NOVEL PYRROLE DERIVATIVES
  申请人：University of Leicester

  公开号：US20140309193A1

  公开（公告）日：2014-10-16

  There are provided inter alia compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4a and R 4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.

  其中提供了式（I）的化合物，其中R1、R2、R3、R4a和R4b如规范中定义，并且它们在治疗中的使用，特别是在治疗细菌（例如肺炎球菌）感染方面。